Amylose AA

Amylose AA

Yilmaz S et al. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever Rheumatology (Oxford). 2015 Mar;54(3):564-5Lire le résumé
Hamanoue S et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016 Jul;26(4):610-3Lire le résumé
Lane T et al.Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2017 Sep;24(3):189–93. Lire le résumé
Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid. 2018 Jan 2;25(1):37–45.Lire le résumé
Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of
secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine. 2017 Aug;96(34):e7859.

Stankovic Stojanovic K, Georgin-Lavialle S, Poitou C, Buob D, Amselem S, Grateau G, et al. AA amyloidosis is an emerging cause of nephropathy in obese patients. European Journal of Internal Medicine. 2017 Apr;39:e18–20.
Lire le résumé

Complément de résumé
Okuda Y,Yamada T, Ueda M, Ando Y. First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Internal Medicine [Internet]. 2019 [cited 2018 Oct 29]; Available from: Lire le résumé
, Calderaro JLetouzé E, Bayard Q, Boulai A, Renault V, Deleuze J-F, et al. Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine. 2018 Sep 20;379(12):1178–80.Lire le résumé
Kisla Ekinci RM, Balci S, Bisgin A, Hershfield M, Atmis B, Dogruel D, et al. Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. Pediatrics. 2018 Nov;142(5):e20180948

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine. 2014 Mar 6;370(10):911–20

Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. The Journal of Rheumatology. 2015 Aug;42(8):1532–4
Lire le résumé
1. Sarıtaş H, Sendogan DO, Kumru G, Sadioglu RE, Duman N, Erturk S, et al. Long-term Results of Kidney Transplantation in Patients With Familial Mediterranean Fever and Amyloidosis. Transplant Proc [Internet]. août 2019 [cité 26 août 2019]
2. Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, et al. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series. Transplant Proc [Internet]. août 2019 [cité 26 août 2019]
Lire le résumé
Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid. 2 janv 2020;27(1):1‑12.Lire le résumé
Sikora J, Kmochová T, Mušálková D, Pohludka M, Přikryl P, Hartmannová H, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int. sept 2021;S008525382100867X. Lire le résumé